Literature DB >> 1255313

Constrictive pericarditis with dwarfism in two siblings (mulibrey nanism).

G R Cumming, D Kerr, C C Ferguson.   

Abstract

Two siblings with marked dwarfism, now 11 and 19 years of age, have been followed from infancy. The girl had frequent episodes of pneumonitis and presented at age 4 years with hepatic enlargement and ascites which proved to be due to constrictive pericarditis. The boy presented with growth failure and pseudohydrocephalus. He had fibrous dysplasia of the tibia and a pathologic fracture; acute hepatic congestion followed physical activity at age 13 years and led to the diagnosis of constrictive pericarditis. Muscle function was normal, there was no evidence for a primary liver disorder, and mental development was normal so that the coined word "mulibray" seemed inappropriate. Pericardiectomy produced only partial improvement; both patients have hepatic enlargement and continue to need diuretics. A third patient with dwarfism, frequent respiratory infections, and pericardial calcification has certain features of the syndrome.

Entities:  

Mesh:

Year:  1976        PMID: 1255313     DOI: 10.1016/s0022-3476(76)80008-x

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  3 in total

1.  Assignment of the mulibrey nanism gene to 17q by linkage and linkage-disequilibrium analysis.

Authors:  K Avela; M Lipsanen-Nyman; J Perheentupa; C Wallgren-Pettersson; S Marchand; S Fauré; P Sistonen; A de la Chapelle; A E Lehesjoki
Journal:  Am J Hum Genet       Date:  1997-04       Impact factor: 11.025

2.  Antibody deficiency and isolated growth hormone deficiency in a girl with Mulibrey nanism.

Authors:  A Haraldsson; C J van der Burgt; C M Weemaes; B Otten; J A Bakkeren; G B Stoelinga
Journal:  Eur J Pediatr       Date:  1993-06       Impact factor: 3.183

3.  Mulibrey nanism: clinical features and diagnostic criteria.

Authors:  N Karlberg; H Jalanko; J Perheentupa; M Lipsanen-Nyman
Journal:  J Med Genet       Date:  2004-02       Impact factor: 6.318

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.